ORTHOFLEX one

Product Specifications

Composition	Cross-linked Hyaluronic Acid + Chondroitin Sulfate
HA Concentration	60 mg / 3 ml
CS Concentration	90 mg / 3 ml
Molecular Weight	3.0 MilDa (high molecular weight)
Volume	3 ml prefilled syringe
Treatment	1 injection per treatment (single dose)
Effect Duration	Up to 1 year
Application	All synovial joints (knee, hip, ankle, shoulder, elbow, wrist, fingers, toes, TMJ, facet joints)
Sterilization	Autoclave
Technology	Biofermentation + Cross-linking
Shelf Life	2 years
Storage	+2°C to +25°C, original packaging, do not freeze
Certifications	CE, ISO 13485, GMP — Class III Medical Device

What is ORTHOFLEX one?

ORTHOFLEX one is the first and only commercial viscosupplement combining HA (hyaluronic acid) and CS (chondroitin sulfate) in the treatment of degenerative joint disease.

It is a sterile, viscoelastic solution containing two highly purified cross-linked biopolymers: hyaluronic acid at 60 mg/3 ml and chondroitin sulfate at 90 mg/3 ml. The high molecular weight (3.0 MilDa) guarantees excellent efficiency and a strong therapeutic effect.

ORTHOFLEX one is presented in a prefilled, sterile, single-dose syringe — administered as 1 injection per treatment.

Unique Cross-Linked Formula

Hyaluronic Acid

Major component of synovial fluid and cartilage. Provides lubrication and cushioning, acts as a shock absorber, and has analgesic, anti-inflammatory, and antioxidant effects.

Chondroitin Sulfate

Delivers nutrients to joint cartilage, stimulates new cartilage growth, blocks cartilage-degrading enzymes, and provides cartilage regeneration — especially useful in severe OA (grade III and IV).

Using Chondroitin Sulfate as a cross-linking agent increases bio-compatibility and bio-degradability, delays cartilage degeneration, and supports regeneration.

Indications

Osteoarthritis of any synovial joint
Post-arthroscopy pain relief
Following meniscus repair procedure
Following crossed ligament reconstruction
Auxiliary treatment for osteochondral defects
Severe OA grades III and IV (cartilage regeneration)

Treatment Protocol

ORTHOFLEX one is administered as a single dose per treatment. If treatment is bilateral, a separate syringe should be used for each joint. The effect can be maintained for up to 1 year. Any joint effusion should be removed by aspiration before injection. An articular rest of approximately 24 hours is recommended post-injection.

Clinical Advantage

One Injection. Up to One Year of Relief.

Traditional HA injectables require 3 to 5 weekly injections per treatment cycle. ORTHOFLEX one changes this with a single-dose formula — high molecular weight cross-linked HA (3.0 MilDa) combined with Chondroitin Sulfate provides a sustained effect lasting up to 12 months.

The cross-linking technology using Chondroitin Sulfate as the cross-linker — instead of toxic chemical agents — increases bio-compatibility, delays enzymatic degradation, and supports cartilage regeneration even in severe Grade III–IV osteoarthritis.

First HA + CS viscosupplement on the market
Single dose per treatment — superior patient compliance
High MW 3.0 MilDa for long-lasting effect
Effective in severe OA (Grade III and IV)
Biocompatible cross-linking — no toxic chemical agents